Atopic dermatitis trial using existing registry data
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial looks at how well two eczema treatments work by using data from a patient registry. It may help people with moderate to severe eczema who have had symptoms for at least 3 years.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had eczema symptoms for at least 3 years
- Your eczema covers at least 10% of your body surface area
- Your eczema score (EASI) is 16 or higher
- You do not have any reason you cannot take upadacitinib or dupilumab
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a pill called upadacitinib (a JAK inhibitor) can help adults with moderate-to-severe atopic dermatitis (eczema) that didn't improve enough with dupilumab. You may be able to join if your eczema is still active despite using dupilumab for at least 4 months.
This study compares two types of eczema treatments—upadacitinib and biologics—to see how well they help adults with moderate-to-severe atopic dermatitis achieve minimal disease activity. It may help you understand which treatment option could work best for your eczema.
This study tests whether an oral medicine (upadacitinib) works as well as a shot (dupilumab) for children aged 2 to 12 with moderate to severe eczema. It aims to see which treatment better controls symptoms like itching and skin rashes.
This study compares a new injectable medicine (IBI3027) to an approved one (Dupilumab) for people with moderate-to-severe eczema. If you join, you'll receive one of the two treatments to see if the new one works as well for reducing itching and skin symptoms.
This study is a real-world registry that collects information from adults with atopic dermatitis (eczema) to track how newly started treatments work and how safe they are over time. It may help researchers and doctors better understand medication effects in everyday care.
This study is a long-term registry for adolescents and adults with atopic dermatitis (eczema) who are starting or switching to a systemic medication (a drug that works throughout the body). It will track how these treatments work in real life and how patients feel over time.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.